Brokers Offer Predictions for Tenax Therapeutics Inc’s Q2 2019 Earnings (TENX)
Tenax Therapeutics Inc (NASDAQ:TENX) – Zacks Investment Research issued their Q2 2019 earnings estimates for shares of Tenax Therapeutics in a report released on Thursday, May 30th. Zacks Investment Research analyst J. Vandermosten expects that the specialty pharmaceutical company will earn ($0.45) per share for the quarter. Zacks Investment Research also issued estimates for Tenax Therapeutics’ Q3 2019 earnings at ($0.44) EPS, Q4 2019 earnings at ($0.40) EPS and FY2021 earnings at ($1.31) EPS.
Separately, ValuEngine upgraded shares of Tenax Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, April 4th.
A number of institutional investors have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in Tenax Therapeutics in the first quarter valued at approximately $39,000. Geode Capital Management LLC acquired a new stake in Tenax Therapeutics in the fourth quarter valued at approximately $33,000. Bank of New York Mellon Corp acquired a new stake in Tenax Therapeutics in the fourth quarter valued at approximately $46,000. Renaissance Technologies LLC boosted its position in Tenax Therapeutics by 47.0% in the first quarter. Renaissance Technologies LLC now owns 242,241 shares of the specialty pharmaceutical company’s stock valued at $489,000 after buying an additional 77,500 shares in the last quarter. Finally, BlackRock Inc. boosted its position in Tenax Therapeutics by 95,450.6% in the first quarter. BlackRock Inc. now owns 599,102 shares of the specialty pharmaceutical company’s stock valued at $1,210,000 after buying an additional 598,475 shares in the last quarter. Hedge funds and other institutional investors own 16.29% of the company’s stock.
About Tenax Therapeutics
Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Recommended Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.